News Daily News Before a Cardiomyopathy Diagnosis, TTR Destabilization Portends Higher Mortality Yael L. Maxwell December 12, 2024
News Conference News HFSA 2024 Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM L.A. McKeown October 04, 2024
News Conference News ESC 2024 HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM L.A. McKeown August 30, 2024
News Daily News Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B Michael O'Riordan June 24, 2024
News Daily News FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy L.A. McKeown October 10, 2023
News Daily News Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy Michael O'Riordan May 06, 2019
News Industry News FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis May 06, 2019